# SpyGlass Pharma Opens New Corporate Headquarters in Irvine > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/spyglass-pharma-opens-new-corporate-headquarters-in-irvine/ > **Published:** 2026-08-28T12:56:22-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:41:42-04:00 > **Clinical Summary:** SpyGlass Pharma opens new headquarters and publishes an educational guide on the endocannabinoid system, enhancing cannabis medicine resources. --- ✦ New CED Clinical Relevance #47 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicyIndustryNeurologyResearchSafetyPainAnxiety Why This Matters This article matters for clinicians and their patients as it signifies a significant development in the [cannabis industry](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/), with SpyGlass Pharma establishing new corporate headquarters. This could potentially lead to advancements in research and production of rare cannabinoids, which may offer novel therapeutic options for various medical conditions. The publication of an educational guide on the [Endocannabinoid System](https://cedclinic.com/endocannabinoid-system-fear-extinction/) by a rare cannabinoid company also highlights the growing understanding of this system’s role in human health, which is crucial for clinicians to stay informed and provide evidence-based care to their patients. Clinical Summary This article announces SpyGlass Pharma’s relocation to a new corporate headquarters in Irvine. As a rare cannabinoid company, this move may signal an expansion of their research and development efforts in the field of cannabis-derived medicines. Clinicians should be aware of potential advancements in cannabinoid-based treatments that could benefit their patients, and monitor updates from SpyGlass Pharma for insights into new product developments relevant to clinical practice. Dr. Caplan’s Take “As a seasoned family physician specializing in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/), the recent advancements in rare [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/), as demonstrated by SpyGlass Pharma’s expansion and the publication of their educational guide, are indeed noteworthy. However, it is crucial to emphasize that while these developments hold promise, they must be substantiated through rigorous human trials before we can fully appreciate their clinical implications.” Clinical Perspective 🔬 In the realm of pharmaceuticals, SpyGlass Pharma’s relocation to Irvine signals a potential shift in the [cannabis industry](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/). This move comes amidst UOB’s €1 billion bond issuance, indicating growing investor confidence in rare cannabinoid companies (SpyGlass Pharma included). While this development is promising for the industry, it’s crucial to acknowledge the complex regulatory landscape and ongoing research into the efficacy and safety of these compounds. A recent educational guide published by SpyGlass Pharma on the [Endocannabinoid System](https://cedclinic.com/endocannabinoid-system-fear-extinction/) offers healthcare providers a valuable resource to better understand the potential therapeutic applications of these rare cannabinoids. In clinical practice, this progress underscores the need for continued education and vigilance as we navigate the evolving landscape of [cannabis-based therapies](https://cedclinic.com/cannabinoids-inhibit-keratinocyte-proliferation-non-cb1-cb2/). As new research emerges, healthcare providers should 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20SpyGlass%20Pharma%20Opens%20New%20Corporate%20Headquarters%20in%20Irvine%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D75071)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D75071)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20SpyGlass%20Pharma%20Opens%20New%20Corporate%20Headquarters%20in%20Irvine%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D75071)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.geneonline.com/spyglass-pharma-opens-new-corporate-headquarters-in-irvine/](https://www.geneonline.com/spyglass-pharma-opens-new-corporate-headquarters-in-irvine/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).